Novo Nordisk Targets Five Multi-Blockbusters by 2030 as Oral Wegovy Gains Traction

Novo Nordisk outlined an updated growth strategy at its Capital Markets Day, maintaining diabetes and obesity as core priorities while expanding into blood and endocrine disorders, liver disease, and cardiovascular conditions. The company is also increasing its focus on consumer-facing prescription medicine channels, signaling broader commercialization ambitions beyond its current metabolic-disease franchise.